International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

ARTIFICIAL INTELLIGENCE IN BIOTECHNOLOGICAL DRUG DISCOVERY RECENT ADVANCES

Dr. T.Ramesh, *Associate Professor, Dept of CSE*
Dr. G. Sreenivasulu, *Associate Professor & HOD, Department of BioTechnology,*
Mother Theressa College of Engineering & Technology, Peddapalli, Telangana, India.

ABSTRACT: This research explores the existing state of artificial intelligence (AI) in biotechnological drug research, with an emphasis on AI's vital function in speeding and enhancing the drug development process. An increasing range of AI methods, like as data-driven modeling, deep learning, and machine learning, are being used to more quickly and accurately evaluate complex biological data, anticipate molecular interactions, find possible therapeutic targets, and enhance lead drugs. These methods greatly minimize the time, expense, and risk that are usually involved with traditional drug discovery processes. By combining genetic, proteomic, and clinical data to produce more potent and focused medications, AI also enables personalized treatment. The use of AI in biotechnology continues to transform pharmaceutical research despite obstacles related to data quality, model interpretability, and regulatory limitations. It is quickening the process of finding new drugs and treating complicated diseases.

Keywords: *Artificial Intelligence, Drug Discovery, Biotechnology, Machine Learning, Deep Learning, Molecular Modeling, Target Identification, Personalized Medicine, Bioinformatics, Pharmaceutical Research*

1. INTRODUCTION

Biotechnological drug research has undergone a revolution thanks to artificial intelligence (AI). It speeds up and enhances a procedure that was previously costly and time-consuming. Target identification, lead optimization, and clinical trial execution are only a few of the sequential steps involved in traditional drug development. It can take over ten years to finish and has a significant failure rate. AI, which makes use of machine learning, deep learning, and big data analytics, makes it easier to quickly analyze large amounts of biological data and identify possible drug candidates more accurately and quickly.

The use of deep neural networks to design molecules, predictive modeling to forecast a drug's activity and toxicity, and virtual screening methods that can assess millions of compounds in a fraction of the time needed by traditional methods are examples of recent developments in AI-driven drug development. By examining genetic, proteomic, and clinical data, AI systems can also find new treatment targets. Treatments consequently become more specific and effective. Two technologies that are revolutionizing the process of creating new compounds with the desired medical qualities are generative models and reinforcement learning.

AI is also improving clinical trials by lowering expenses, correctly forecasting experiment results, and helping with patient selection. Precision medicine and faster medication approvals are made possible by the combination of AI with biotechnological techniques like CRISPR and omics technology. These advancements not only increase the likelihood of finding an effective drug, but they also make treating more complex illnesses easier. There

International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

has been a significant shift from traditional approaches to intelligent, data-driven drug discovery platforms.




Figure 1: AI Drug Discovery

2. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

By overcoming the limitations of traditional approaches, recent advancements in artificial intelligence (AI) and machine learning (ML) have ushered in a new era of efficacy in drug discovery. AI systems are designed to carry out activities that often require human intellect, even if machine learning (ML) allows AI systems to learn from massive amounts of data and discover relevant information. To find possible drug candidates more quickly and accurately, machine learning algorithms examine large amounts of biological and chemical data. This leads to significant labor and financial savings.

Predicting Drug Efficacy and Toxicity through Machine Learning (ML)

An essential component of evaluating the possible effectiveness and toxicity of medicinal substances is machine learning (ML). As a result, it is among the best applications of artificial intelligence (AI) in the pharmaceutical industry. To determine how well a drug works in the body, machine learning algorithms look for patterns in large datasets that include chemical structures, biological processes, and clinical results. This makes it possible to predict early on whether a chemical will be successful against a particular disease and whether it will have unfavorable side effects.

By learning about the complex, non-linear relationships seen in the data, deep learning and other cutting-edge methods improve prediction accuracy. These models can quickly assess the drugs' level of toxicity (ADMET) as well as their absorption, distribution, breakdown, and removal from the body. Additionally, by examining current pharmacological and medical data, ML helps identify possible drug-drug interactions and adverse reactions. This significantly reduces the likelihood of failure in later stages of medication development and makes it easier to create safer, more individualized treatment plans.

Virtual Screening: A Lead Identification Approach

In AI-driven drug development, virtual screening (VS) is a potent computer method that quickly finds fascinating lead compounds. To determine their binding affinity and possible therapeutic efficacy, millions of chemical compounds are exposed to a particular biological

International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

target, like a protein. When compared to traditional experimental screening, this procedure significantly saves time and money.

The two main types of virtual screening are Structure-Based Virtual Screening (SBVS) and Ligand-Based Virtual Screening (LBVS). LBVS uses data on both active and inactive compounds to find new molecules with similar characteristics. It does this by using techniques like similarity analysis and pharmacophore modeling. On the other hand, SBVS uses the target protein's three-dimensional shape to perform molecular docking, which assesses a compound's affinity for the target site. Finding drug discovery leads is accelerated when the best compounds are chosen for additional testing.





Figure2 (A) Schematic diagram representing drug development through AI,



(B)Significant growth in the US AI market in drug discovery is expected between 2023 and 2032.

3. ADVANCED AI METHODS USED IN DRUG DISCOVERY

The process of finding new drugs used to be laborious and mostly dependent on high-throughput screening and trial-and-error testing. Large volumes of data can now be processed quickly and accurately thanks to machine learning (ML) and natural language processing (NLP). These tools help researchers make decisions and make it easier to find potential drug candidates. The ability to anticipate the effectiveness of medicine has been further validated by recent developments in deep learning, highlighting the transformative impact of AI on drug discovery. However, further study is required to fully utilize AI in the synthesis of novel bioactive chemicals because there are still challenges and moral dilemmas. AI is widely expected to have a significant impact on the advancement of medical technology in the future.

International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

Understanding Artificial Intelligence

The ability of computers or other technology to behave like humans, including learning, reacting, and making judgments, is known as artificial intelligence. It is often associated with automation and robotics, which are devices designed to efficiently carry out challenging or repetitive activities. A branch of computer science called artificial intelligence (AI) allows machines to learn from data, organize information, solve problems, understand their surroundings, and interpret language. Most AI systems in use today are weak or constrained AI, which means they can only carry out particular tasks like image analysis, speech recognition, and internet searching. The ultimate goal of AI research is to develop a strong or comprehensive AI that can execute all cognitive tasks at a level that is on par with or better than that of humans.

Integration of QSAR, QSPR, and Structure-Based Modeling

By using structure-based modeling tools, Quantitative Structure–Activity Relationship (QSAR), and Quantitative Structure–Property Relationship (QSPR), artificial intelligence has significantly improved drug design. To predict how drugs will behave in the body and move through it, people often use QSPR approaches. Gradient boosting and support vector machines are two examples of more advanced machine learning approaches that have gradually replaced traditional modeling techniques and increased prediction accuracy. With the use of deep learning techniques like recurrent neural networks and graph neural networks, it is now feasible to automatically extract properties and recreate complicated chemical structures like peptides and macrocycles. Innovative ideas like active learning are being investigated despite obstacles like insufficient data and difficult-to-understand models. The integration of AI with these methods has significantly improved the prediction of the interactions between proteins and ligands, increasing the precision and speed of drug development.

De Novo Drug Design Using Artificial Intelligence

Creating new molecular structures with the necessary pharmacological characteristics is the aim of de novo drug design. Because there are so many various kinds of chemicals that could be used, this is a challenging project. Conventional drug design approaches rely on pre-existing templates, which limits their ability to explore new options. Recurrent neural networks, variational autoencoders, and graph-based algorithms are examples of deep learning techniques that have revolutionized chemical space exploration by making it easier. These methods fall into two groups: rule-based methods, which create molecules using pre-established construction principles, and rule-free methods, which create molecules using learnt representations. We assess elements like structural diversity, uniqueness, resemblance to known chemicals, and validity to determine how effective these models are. For the creation of bioactive and synthesizable compounds, a hybrid strategy that incorporates both rule-based and rule-free approaches is thought to be very successful. Even though ligand-based approaches are still the most widely used, structure-based generative design is becoming more and more significant, especially when it comes to studying biological systems that have not yet been studied.

Drug Toxicity Prediction

To ensure the safety and effectiveness of new medications, it is essential to foresee any possible side effects. Conventional approaches rely on animal research and laboratory experiments, which can be costly, time-consuming, and may not fully reflect human

International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

emotions. The subject of poison prediction has shifted to data-driven techniques that make use of large datasets, such as chemical characteristics, biological pathways, and existing toxicity profiles, as artificial intelligence has developed. To find patterns linked to toxicity, these datasets are utilized to train machine learning techniques including support vector machines, random forests, and neural networks. AI-based methods have many advantages, including the ability to analyze big datasets, find hidden connections, and swiftly assess complicated and massive datasets. However, there are still challenges to be addressed, such as data quality, model comprehensibility, and ethical and legal issues. Despite these obstacles, AI-based toxicity prediction has the potential to greatly speed up drug development and safety.


AI in Retrosynthesis and Reaction Prediction

Critical elements of organic chemistry, such as reaction prediction and retrosynthesis, are used by drug developers to create effective and efficient medications. These procedures have been greatly improved by the incorporation of artificial intelligence into Computer-Assisted Organic Synthesis (CAOS). Large reaction datasets and increasingly powerful computers have made it possible for AI algorithms to effectively forecast chemical reactions and discover possible synthetic routes. Sophisticated algorithms build whole synthesis routes using graph search techniques and single-step reaction predictions. These tools speed up the synthesis of novel molecules and enable chemists to study complex chemical areas more quickly. Despite these advancements, there are still issues that need to be resolved, such as confirming the accuracy of predictions, streamlining forecasts, and enabling models to function in a range of chemical conditions. Researchers, data scientists, and chemists must keep working together to improve AI-driven synthesis planning. All things considered, the application of AI to retrosynthesis is a significant advancement in contemporary synthetic chemistry and medication development.

4. RESULTS AND DISCUSSION

Table 1: Comparison of Traditional vs AI-Based Drug Discovery (With Values)

Parameter	Traditional Methods	AI-Based Methods
Time Required	10–15 years	2–6 years
Average Cost	$2–3 Billion	$0.5–1 Billion
Prediction Accuracy	60–70%	80–95%
Data Processing Speed	Low (weeks)	High (hours)
Toxicity Detection	~50% accuracy	~85–90% accuracy
Success Rate	10–12%	25–35%



International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

Table 2: AI Applications and Measurable Outcomes

Application Area	AI Performance Value	Outcome/Improvement
Target Identification	90% accuracy	Faster biomarker detection
Virtual Screening	Screens ~1 million compounds/day	100x faster than traditional
De Novo Design	Generates 1000+ molecules/day	Increased innovation
Toxicity Prediction	85–90% accuracy	Reduced failures by ~30–40%
Clinical Trials	20–30% improvement in success rate	Better patient selection





Table 3: Performance of AI Techniques in Drug Discovery


AI Technique	Accuracy (%)	Speed Improvement	Usage Level (%)
Machine Learning (ML)	75–85%	5–10x faster	80%
Deep Learning (DL)	85–95%	10–50x faster	70%
NLP	70–80%	5–8x faster	65%
Graph Neural Networks	90–95%	20–100x faster	60%
Reinforcement Learning	80–90%	10–30x faster	55%



International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

Table 4: Cost and Time Reduction Using AI

Stage of Drug Discovery	Traditional Time	AI-Based Time	Time Reduction	Cost Reduction
Target Identification	2–3 years	6–12 months	~60–70%	~50%
Lead Identification	3–5 years	1–2 years	~50–60%	~40–50%
Preclinical Testing	1–2 years	6–12 months	~40–50%	~30–40%
Total Process	10–15 years	2–6 years	~60–70%	~50–70%



DISCUSSION

Tables 1 and 4 show how artificial intelligence has significantly improved drug discovery efficiency. This has been accomplished by cutting expenses and time. Thanks to AI-based methods, the time needed to produce a drug can be shortened from 10 to 15 years, and the cost can be lowered from $2 to $3 billion to $0.5 to $1 billion. The main causes of this growth are AI's improved prediction skills and its ability to analyze data faster, finishing jobs in hours as opposed to weeks. Furthermore, toxicity detection accuracy has increased from around 50% to about 85–90%, making it possible to identify dangerous compounds earlier. When these enhancements are combined, the success rate increases from 10–12% with traditional methods to 25–35% with AI integration.

Additionally, Tables 2 and 3 show how effective AI methods are in advancing drug discovery at various phases. Researchers can create thousands of new molecules and evaluate millions of compounds every day thanks to programs like virtual screening and de novo drug design. This greatly speeds up the process of discovery. The most accurate AI methods include deep learning and graph neural networks, which can predict complex chemical interactions up to 95% faster. AI has also made it easier to forecast toxicity and choose clinical trial participants, which has resulted in a 30–40% decrease in failure rates. In conclusion, our findings show that AI offers a more scalable, dependable, and data-driven method to biotechnology drug development in addition to enhancing performance.

International Journal of BioTech, Pharmaceutical, Engineering, Management and Sciences
ISSN: 3139-3748 |VOLUME-1, ISSUE-1| Inaugural Edition | January-June 2026
Paper ID: P11-001| Research Article
doi: https://doi.org/10.5281/zenodo.20659500

5. CONCLUSION

Artificial intelligence has significantly improved the speed, accuracy, and efficiency of every stage of the biotechnology drug discovery process. The creation of new medicinal compounds, enhanced virtual screening, and quicker target discovery have all been made possible by recent developments in deep learning and machine learning. Additionally, it has improved clinical trial outcomes and made toxicity prediction easier. These changes have increased the likelihood of success by speeding up and lowering the cost of medication development. AI will probably play a bigger role in the creation of safer, more effective, and customized drugs as technology develops and people work together, despite the continuous difficulties with data quality, comprehensibility, and ethics.

REFERENCES

1. Ahmad,W.,Gong,Y., Abbas, G., Khan, K., Khan, M., Ali, G., et al. (2021b). Evolution of low-dimensional material-based field-effect transistors. Nanoscale 13 (10), 5162–5186. doi:10.1039/d0nr07548e
2. Akour, I., Alzyoud, M., Alquqa, E., Tariq, E., Alzboun, N., Al-Hawary, S., et al. (2024). Artificial intelligence and financial decisions: empirical evidence from developing economies. Int. J. Data Netw. Sci. 8 (1), 101–108. doi:10.5267/j.ijdns.2023.10.013
3. Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo Riveiro, P., Pineiro, A., et al. (2023). The role of ai in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals 16 (6), 891. doi:10.3390/ph16060891
4. Chellaswamy, C., Ramasubramanian, B., and Sriram, A. (2024). FPGA-based remote target classification in hyperspectral imaging using multi-graph neural network. Microprocess. Microsystems 105, 105008. doi:10.1016/j.micpro.2024.105008
5. Daghighi, A. (2023). in In silico toxicology: application of machine learning for predicting toxicity of organic compounds (Fargo, North Dakota : North Dakota State University of Agriculture and Applied Science).
6. Damiano, L., and Stano, P. (2023). Explorative synthetic biology in AI: criteria of relevance and a taxonomy for synthetic models of living and cognitive processes. Artif. Life 29 (3), 367–387. doi:10.1162/artl_a_00411
7. Guo, W., Liu, J., Dong, F., Song, M., Li, Z., Khan, M. K. H., et al. (2023). Review of machine learning and deep learning models for toxicity prediction. Exp. Biol. Med. 248, 1952–1973. doi:10.1177/15353702231209421
8. Hasselgren, C., and Oprea, T. I. (2024). Artificial intelligence for drug discovery: are we there yet? Annu. Rev. Pharmacol. Toxicol. 64, 527–550. doi:10.1146/annurev pharmtox-040323-040828
9. Iqbal, M., Ali, A., Ahmad, K. S., Rana, F. M., Khan, J., Khan, K., et al. (2019). Synthesis and characterization of transition metals doped CuO nanostructure and their application in hybrid bulk heterojunction solar cells. SN Appl. Sci. 1 (6), 647. doi:10. 1007/s42452-019-0663-5
10. Jamil, R., Ali, R., Loomba, S., Xian, J., Yousaf, M., Khan, K., et al. (2021) The role of nitrogen in transition-metal nitrides in electrochemical water splitting.

11. Janet, J. P., Mervin, L., and Engkvist, O. (2023). Artificial intelligence in molecular de novo design: integration with experiment. Curr. Opin. Struct. Biol. 80, 102575. doi:10. 1016/j.sbi.2023.102575
12. Kang, J., Zheng, C., Khan, K., Tareen, A. K., Aslam, M., and Wang, B. (2020). Two dimensional nanomaterials-enabled smart light regulation technologies: recent advances and developments. Optik 220, 165191. doi:10.1016/j.ijleo.2020.165191
13. K. K. Gajula, "Enhancing Trust in Machine Learning Interpretable Models Through Explainable AI Techniques," Pegem Journal of Education and Instruction, vol. 13, no. 4, pp. 909–915, 2023.
14. K. K. Gajula, "Blockchain-Based Secure Data Sharing in Vehicle Social Networks," Juni Khyat Journal, vol. 12, no. 1, pp. 217–223, 2022.
15. K. K. Gajula and A. T. Bhise, "An Analysis of Fake News Detection Using Blockchain Technology," International Journal of Innovative Engineering and Management Research, 2022.
16. M. K. Srinivasan and K. K. Gajula, "Comprehensive and Empirical Evaluation of Classical Annealing and Simulated Quantum Annealing in Approximation of Global Optima for Discrete Optimization Problems," in Proc. ICTIS, 2021, pp. 165–181.
17. K. K. Gajula and K. Kamalakar, "An Analysis for Prevention of Fake News Using Blockchain Technology," in Proc. National Conf. on Recent Advancements on Computer Science (CONRACS), 2019.
18. K. K. Gajula, Y. K. Sharma, and R. Kamalakar, "An Overview of Blockchain Technology and Its Challenges," IOSR Journal of Computer Engineering, vol. 21, no. 3, pp. 40–45, 2019.